Brigatinib (trade name: Alunbrig) has been approved in Germany since November 2018 for the treatment of advanced non-small-cell lung lung cancer in adults. It can be used in patients who have certain mutated cancer cells that can lead to faster tumor growth. These patients should also have already had treatment with crizotinib.
- Small-cell lung carcinoma (SCLC)
- Non-small-cell lung cancer (NSCLC)
NSCLC is surgically removed. But sometimes the tumor has already become too large or the cancer has spread to other parts of the body (metastasis) through the blood or lymphatic system. It is then called advanced lung cancer.
Some people with non-small-cell lung cancer have an abnormal enzyme in the tumor tissue called anaplastic lymphoma kinase (ALK). The full name of the cancer is then ALK-positive non-small-cell lung cancer. The enzyme ALK can lead to uncontrolled growth of the tumor tissue.
Brigatinib is used to try to block the ALK enzyme, thereby inhibiting further tumor growth.
Brigatinib is available in the form of tablets, in the doses 30 mg, 90 mg and 180 mg.
For the first seven days the dose is 90 mg brigatinib. After that it is increased to 180 mg brigatinib.
The medicine ceritinib is a possible treatment option for people with ALK-positive non-small-cell lung cancer who have already had treatment with crizotinib.
In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of brigatinib compared with the standard treatment (ceritinib) in people with ALK-positive non-small-cell lung cancer who have already had treatment with crizotinib.
But the manufacturer didn’t provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of brigatinib (Alunbrig).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Brigatinib (NSCLC) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A19-08. April 11, 2019. (IQWiG reports; Volume 754).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.